Novartis gains FDA approval for Cosentyx in PMR and ADC deal with OBI Pharma
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis (SWX:NOVN) reported US FDA approval of Cosentyx as the first anti IL 17 biologic for polymyalgia rheumatica. The new Cosentyx indication targets patients with polymyalgia rheumatica who currently rely heavily on long term steroid treatment. Novartis agreed a global…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRegulatory approval and a new licensing deal at a large pharma group are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica.
- 02Novartis signed a global antibody drug conjugate licensing and development deal with OBI Pharma.
- 03The new use targets patients who rely heavily on long-term steroid treatment.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Novartis AG127.24 CHFMarket closedtoday -3.22%Positive Novartis AG151.22 USDMarket closedtoday -2.57%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets